Sana Biotechnology (NASDAQ:SANA) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Sana Biotechnology (NASDAQ:SANA) from a hold rating to a sell rating in a research report released on Saturday.

Other research analysts have also issued reports about the company. JMP Securities set a $8.00 price target on Sana Biotechnology in a research report on Thursday, October 30th. Citizens Jmp boosted their target price on shares of Sana Biotechnology from $5.00 to $8.00 and gave the stock a “market outperform” rating in a report on Thursday, October 30th. Wedbush raised their price target on shares of Sana Biotechnology from $5.00 to $6.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Citigroup reaffirmed an “outperform” rating on shares of Sana Biotechnology in a research report on Thursday, October 30th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Sana Biotechnology in a research report on Wednesday, October 8th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Sana Biotechnology currently has an average rating of “Moderate Buy” and an average price target of $8.33.

Sana Biotechnology Trading Up 1.9%

SANA opened at $3.29 on Friday. Sana Biotechnology has a 12-month low of $1.26 and a 12-month high of $7.30. The business’s fifty day simple moving average is $4.20 and its 200-day simple moving average is $3.49. The company has a market capitalization of $876.34 million, a price-to-earnings ratio of -3.39 and a beta of 1.94.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.03. On average, equities research analysts predict that Sana Biotechnology will post -1.16 EPS for the current year.

Hedge Funds Weigh In On Sana Biotechnology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC lifted its position in Sana Biotechnology by 673.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 10,911 shares of the company’s stock worth $30,000 after acquiring an additional 9,501 shares during the period. Hoey Investments Inc. purchased a new position in shares of Sana Biotechnology in the second quarter worth about $33,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Sana Biotechnology during the third quarter worth about $36,000. TD Waterhouse Canada Inc. purchased a new stake in Sana Biotechnology in the third quarter valued at approximately $37,000. Finally, Lyell Wealth Management LP acquired a new position in Sana Biotechnology in the 3rd quarter worth approximately $37,000. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.